文献速递白血病造血干细胞移植与细胞治疗

多参数流式细胞术检测的微小残留病复发在形态学缓解的急性淋巴细胞白血病患者中的意义

Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission.
PubMed 文献 · Am J Hematol · 2017-02-01

研究纳入2003年1月至2014年9月期间647例新诊断急性淋巴细胞白血病患者,546例诱导及巩固治疗后达微小残留病阴性,其中55例在形态学完全缓解期间出现微小残留病复发。微小残留病复发后中位3个月44例(80%)发生形态学复发;仅6例存活且维持首次完全缓解。

要点

  • 达完全缓解后任何时间经多参数流式细胞术检出微小残留病复发,均与形态学复发高风险相关。
  • 55例微小残留病复发患者中44例(80%)在中位3个月后发生形态学复发。
  • 造血干细胞移植可使部分患者获得长期缓解。

核心结论

  • 达完全缓解后经多参数流式细胞术检出微小残留病复发与形态学复发高风险相关;造血干细胞移植可使部分患者获得长期缓解;需要前瞻性长期微小残留病监测研究及低毒根除微小残留病策略。

研究设计与样本

  • 研究纳入2003年1月至2014年9月期间647例新诊断急性淋巴细胞白血病患者,其中HyperCVAD为基础方案531例、Augmented BFM方案116例。
  • 601例(93%)达完全缓解,546例(91%)达微小残留病阴性;55例在形态学完全缓解期间出现微小残留病复发,为本研究对象。
  • 微小残留病采用6色(2009年前为4色)多参数流式细胞术在完全缓解时及之后多个时间点评估。

主要发现

  • 55例微小残留病复发患者中HyperCVAD为基础方案49例、Augmented BFM方案6例。
  • 微小残留病复发患者中位年龄44岁(范围18-72岁),初诊中位白细胞7.3 K/µL-1(范围0.6-303.8 K/µL-1),中位骨髓原始细胞百分比88%(范围26-98%)。
  • 中位至微小残留病复发时间14个月(范围3-58个月)。
  • 44例(80%)在检出微小残留病复发后中位3个月(范围<1-33个月)发生形态学复发。
  • 微小残留病阳性后至形态学复发前治疗:16例继续维持化疗,15例接受晚期强化,9例异基因造血干细胞移植,9例更换化疗,6例未进一步治疗。

局限性

  • 原文结论提出需要前瞻性长期微小残留病监测研究及低毒根除微小残留病治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We sought to determine the significance of minimal residual disease (MRD) relapse in patients with ALL after achieving MRD negative status following induction and consolidation therapy. Between January 2003 and September 2014, 647 newly diagnosed patients were treated [HyperCVAD-based (n = 531); Augmented BFM (n = 116)]. Six hundred and one (93%) achieved complete remission (CR), and 546 (91%) became MRD negative. Fifty-five patients [HyperCVAD-based (n = 49); Augmented BFM (n = 6)] developed recurrence of MRD while still in morphological CR and are the subjects of this study. MRD was assessed by 6-color (4-color prior to 2009) multi-parameter flow cytometry (MFC) at CR and multiple time points thereafter. Their median age was 44 years (range, 18-72 years), median WBC at initial presentation was 7.3 K/µL-1 (range, 0.6-303.8 K/µL-1 ) and median bone marrow blast percentage 88% (range, 26-98%). The median time to MRD relapse was 14 months (range 3-58 months). Forty-four (80%) patients subsequently developed morphological relapse after median of 3 months (range, <1-33 months) from detection of MRD recurrence. Treatments received after MRD positivity and prior to morphological relapse: 16 continued maintenance chemotherapy; 15 received late intensification; 9 allogeneic stem cell transplant, 9 changed chemotherapy, 6 no further therapy. Only six remain alive and in CR1 and nine are alive after morphological relapse. MRD relapse detected by MFC at any time after achieving CR is associated with a high risk for morphological relapse. SCT can result in long-term remission in some patients. Prospective studies of long-term MRD assessments, together with less toxic treatment strategies to eradicate MRD, are warranted.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Pemmaraju N, Kantarjian H, Jorgensen JL, et al. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. Am J Hematol. 2017. PMID: 28052371. doi:10.1002/ajh.24629

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。